Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-13
2005-09-13
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C514S399000, C546S275100, C546S178000, C546S146000, C548S315400, C548S264200, C548S341100, C548S315100, C548S236000, C548S312100, C548S314700, C544S405000
Reexamination Certificate
active
06943183
ABSTRACT:
The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme
REFERENCES:
patent: 6265422 (2001-07-01), Bikker et al.
patent: WO 98/34921 (1998-08-01), None
PCT International Search Report PCT/US01/12490, Jan. 16, 2002.
Denny William Alexander
Hutchings Richard H.
Johnson Douglas S.
Kaltenbronn James Stanley
Lee Ho Huat
Butterfield Garth
Pfizer Inc
Richardson Peter C.
Stockton Laura L.
LandOfFree
5-substituted tetralones as inhibitors of ras farnesyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-substituted tetralones as inhibitors of ras farnesyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-substituted tetralones as inhibitors of ras farnesyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3418814